More on SNY
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $42.50 |
|
|||
| Open | $42.34 | ||||
| 52 Wk High | $44.76 | ||||
| 52 Wk Low | $36.81 | ||||
| Day High | $42.47 | ||||
| Day Low | $41.86 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 4,085,505 | ||||
- Sanofi wins Japan approval for Sarclisa SC in multiple myeloma
- Press Release: Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple myeloma
- Sanofi (SAN:FP) (SNY) PT Lowered to EUR95 at Deutsche Bank
- Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes
- Form 6-K Sanofi For: Jun 12
- Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
- TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'
- Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
- Form 6-K Sanofi For: Jun 08
- Press Release: Sanofi launches 2026 global employee stock purchase plan
Entities mentioned with SNY
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Genzyme/Sanofi-Aventis | View Related Stories »
- Definitive Agreement | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Show More...
